in this issue
Regions :: North America :: U.S.
AMRI completes acquisition of OsoBio
7:48 AM MDT | July 2, 2014 | Deepti Ramesh
Albany Molecular Research Inc. (AMRI; Albany, NY) says that it has completed the previously announced acquisition of Oso Biopharmaceuticals Manufacturing (OsoBio; Albuquerque, NM). Total consideration paid was $110 million, which AMRI financed with cash on hand. OsoBio is a contract manufacturer of highly complex injectable drug products, including sterile liquid, suspension, and lyophilized formulations. OsoBio's forecast full-year 2014 revenue is $58–60 million, with adjusted Ebitda of $9–10 million, AMRI says. OsoBio’s expertise in...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee